Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
STTK
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.49
vs -0.58
Q2.23
N/A
-0.50
vs -0.65
Q3.23
N/A
-0.65
vs -0.58
Q4.23
N/A
-0.41
vs -0.60
Q1.24
N/A
-0.37
vs -0.49
Q2.24
N/A
-0.42
vs -0.50
Q3.24
N/A
-0.33
vs -0.65
Q4.24
N/A
-0.37
vs -0.41
Q1.25
N/A
-0.28
vs -0.37
Q2.25
N/A
-0.27
vs -0.42
Sales Growth
YoY
Current
Estimates
Q3.22
-89%
212K vs 1.9M
Q4.22
-99%
390K vs 30.1M
Q1.23
NA
57K vs NA
Q2.23
+300%
200K vs 50K
Q3.23
+224%
686K vs 212K
Q4.23
+83%
714K vs 390K
Q1.24
+1856%
1.1M vs 57K
Q2.24
+705%
1.6M vs 200K
Q3.24
+337%
3M vs 686K
Q4.24
-100%
NA vs 714K
Return on Equity
QoQ
Q1.23
-13%
-0.13
vs -0.14
Q2.23
-15%
-0.15
vs -0.13
Q3.23
-24%
-0.24
vs -0.15
Q4.23
-12%
-0.12
vs -0.24
Q1.24
-14%
-0.14
vs -0.12
Q2.24
-19%
-0.19
vs -0.14
Q3.24
-17%
-0.17
vs -0.19
Q4.24
-23%
-0.23
vs -0.17
Institutionnal Ownership
QoQ
Q1.23
49
49
vs 48
2%
Q2.23
41
41
vs 49
-16%
Q3.23
41
41
vs 41
NA
Q4.23
64
64
vs 41
56%
Q1.24
75
75
vs 64
17%
Q2.24
77
77
vs 75
3%
Q3.24
79
79
vs 77
3%
Q4.24
74
74
vs 79
-6%
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
globenewswire.com
16 hours ago
globenewswire.com
17 hours ago
Quote Panel
Key Metrics
Forecast
NaN%2025-Revenue
-193%2025-EPS
93%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Needham
downgradePrevious: Buy
2024-10-02
Now: Hold
Citigroup
downgradePrevious: Buy
2024-10-01
Now: Neutral
H.C. Wainwright
downgradePrevious: Buy
2024-10-01
Now: Neutral
H.C. Wainwright
downgradePrevious: Buy
2024-10-01
Now: Negative
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
NASDAQ
Unprofitable
Unprofitable
-0.04Â ( -4.95%)
Relative Strenght
5
Volume Buzz
-50%
Earning Acce
No
Dist 52w H.
93%Relative Strength
STTK
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|